Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKesson
McKinsey
Citi
Chubb
Federal Trade Commission
Cipla
Queensland Health
Farmers Insurance

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,429,210

« Back to Dashboard

Which drugs does patent 6,429,210 protect, and when does it expire?

Patent 6,429,210 protects PLAVIX and is included in one NDA.

Protection for PLAVIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in forty-three countries.
Summary for Patent: 6,429,210
Title: Polymorphic clopidogrel hydrogenesulphate form
Abstract:Novel orthorombic polymorph of clopidogrel hydrogen sulfate or hydrogen sulfate of methyl (+)-(S)-.alpha.-(2-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5 -acetate and a process for its preparation.
Inventor(s): Bousquet; Andre (Sisteron, FR), Castro; Bertrand (Kremlin-Bicetre, FR), Saint-Germain; Jean (Sisteron, FR)
Assignee: Sanofi-Synthelabo (Paris, FR)
Application Number:09/623,333
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,429,210
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 6,429,210

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi Aventis Us PLAVIX clopidogrel bisulfate TABLET;ORAL 020839-001 Nov 17, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sanofi Aventis Us PLAVIX clopidogrel bisulfate TABLET;ORAL 020839-002 Sep 20, 2007 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,429,210

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France98 07464Jun 15, 1998
PCT Information
PCT FiledJune 10, 1999PCT Application Number:PCT/FR99/01371
PCT Publication Date:December 23, 1999PCT Publication Number: WO99/65915

Non-Orange Book US Patents Family Members for Patent 6,429,210

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,504,030 Polymorphic form of clopidogrel hydrogen sulphate ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Farmers Insurance
Merck
Teva
Julphar
Dow
Daiichi Sankyo
Johnson and Johnson
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.